Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal

CNS Drugs

Volumn 19, Issue 12, 2005, Pages 1049-1055

  Seppälä, Niko ^a,d   Kovio, Carita ^b   Leinonen, Esa ^b,c  

^a Harjavalta Hospital   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d Satakunta Hospital District   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BIPERIDEN; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PIPOTIAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL ARTICLE; DETERIORATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MEDICAL RECORD; MENTAL DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 28844507910     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200519120-00006     Document Type: Article

References (38)

1. Wagstaff A, Bryson H. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995; 5 (5): 370-400
2. Wagstaff A, Perry C. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS Drugs 2003; 17 (4): 273-80
3. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992 Spring; 63 (1): 51-70
4. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57 Suppl. 11: 12-25
5. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995; 21 (4): 579-91
6. Idänpään-Heikkilä J, Alhava E, Olkinuora M, et al. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977 Mar; 11 (3): 193-8
7. Kuha S. The consequences of sudden stopping of clozapine in Finland [abstract]. Proceedings of the Sixth World Congress of Psychiatry 1977; American Psychiatric Association; Honolulu
8. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419-29
9. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002; 16 (7): 473-84
10. Ekblom B, Eriksson K, Lindström LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacol (Berl) 1984; 83 (3): 293-4
11. Shiovitz TM, Welke TL, Tigel PD, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996; 22 (4): 591-5
12. Ahmed S, Chengappa KN, Naidu VR, et al. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 1998 Sep; 59 (9): 472-7
13. Stanilla JK, de Leon J, Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 1997 Jun; 58 (6): 252-5
14. Zesiewicz TA, Borra S, Hauser RA. Clozapine withdrawal symptoms in a Parkinson's disease patient. Mov Disord 2002 Nov; 17 (6): 1365-7
15. Lee JW, Robertson S. Clozapine withdrawal catatonia and neuroleptic malignant syndrome: a case report. Ann Clin Psychiatry 1997 Sep; 9 (3): 165-9
16. Yeh AW, Lee JW, Cheng TC, Wen JK, Chen WH. Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: a case report. Clin Neuropharmacol 2004 Sep-Oct; 27 (5): 216-8
17. Gerlach J, Koppelhus P, Helweg E, et al. Clozapine and haloper-idol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 1974; 50 (4): 410-24
18. Diamond BI, Borison RL. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Psychopharmacol Bull 1986; 22 (3): 900-5
19. Borison RL, Diamond BI, Sinha D, et al. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988; 24 (2): 260-3
20. Meltzer HY, Lee MA, Ranjan R, et al. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology (Berl) 1996 Mar; 124 (1-2): 176-87
21. Tollefson GD, Dellva MA, Mattler CA, et al. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. J Clin Psychopharmacol 1999 Oct; 19 (5): 435-43
22. Chouinard G, Jones BD, Annable L. Neuroleptic-induced super-sensitivity psychosis. Am J Psychiatry 1978 Nov; 135 (11): 1409-10
23. Eklund K. Supersensitivity and clozapine withdrawal. Psychopharmacology (Berl) 1987; 91 (1): 135
24. Parsa MA, al-Lahham YH, Ramirez LF, et al. Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 1993 Apr; 13 (2): 154-5
25. de Leon J, Henighan V, Stanilla JK, et al. Clozapine levels after clozapine discontinuation. J Clin Psychopharmacol 1996 Apr; 16 (2): 193-4
26. Tanriverdi N, Yazici KM. Immediate recurrence of psychotic symptoms after discontinuation of clozapine: a case report. Biol Psychiatry 1996 May 1; 39 (9): 814-5
27. Shore D. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995; 21 (2): 333-7
28. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975 Dec; 132 (12): 1237-45
29. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995 Mar; 52 (3): 173-88
30. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999 Jun; 156 (6): 876-84
31. Guy W. ECDEU Assessment manual for psychopharmacology. Rockville (MD): National Institute of Mental Health, 1976: 218-22
32. Taylor P. Cholinergic agonists. In: Gilman GA, Rall TW, Nies AS, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 122-30
33. Linszen DH, Dingemans PM, Lenior ME, et al. Relapse criteria in schizophrenic disorders: different perspectives. Psychiatry Res 1994 Dec; 54 (3): 273-81
34. Bazire S. Psychotropic drug directory 2002. Snow Hill, Dinton: Mark Allen Publishing Ltd, 2001
35. de Leon J, Stanilla JK, White AO, et al. Anticholinergics to treat clozapine withdrawal. J Clin Psychiatry 1994 Mar; 55 (3): 119-20
36. Meltzer HY. Clozapine withdrawal: serotonergic or dopaminergic mechanisms? Arch Gen Psychiatry 1997 Aug; 54 (8): 760-1
37. Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry 1995 Dec; 52 (12): 1071-2
38. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 Sep; 45 (9): 789-96